PERFORMANCE
Tesamorelin — GHRH analog for visceral fat
Also known as: TH9507, Egrifta
Tesamorelin (Egrifta) is a stabilised 44-amino-acid GHRH analog, FDA-approved for HIV-associated lipodystrophy. Trials show 15–18% reduction in visceral adipose tissue over 26 weeks.
99%+ purity · Janoshik HPLC verified
Prices
Tesamorelin · 10mg
1 vial45€
5-pack180€
Mechanism
Stimulates endogenous GH release while preserving natural pulsatility, driving VAT lipolysis via IGF-1.
Clinical data
Falutz NEJM 2007: 2 mg/day for 26 weeks produced -15.2% VAT vs +5% placebo.
Protocol
Typical 2 mg SC nightly, 12–26 week cycles often paired with resistance training.
Frequently asked questions
Buy in EU?
Yes — research-grade only, EU shipping.
Better than CJC-1295?
More clinical data and stronger VAT outcomes; CJC-1295 DAC has longer duration but less validation.
Research use only. Not for human consumption.